Exelixis and Bristol-Myers Squibb have announced an agreement to extend their research collaboration relating to cardiovascular and metabolic diseases for an additional year, now ending in January 2009. Under the terms of the extension, Exelixis will receive an additional $7.5 million in funding. The collaboration is focused on developing therapies against the Liver X Receptor (LXR). The companies hope to discover and develop drug candidates that will activate LXR, which may cause removal of cholesterol from the body and also suppression of inflammatory responses associated with atherosclerosis.
Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.
Comments